Shares of VBI Vaccines Inc. (NASDAQ:VBIV) have earned a consensus broker rating score of 1.00 (Strong Buy) from the two analysts that cover the stock, Zacks Investment Research reports. Two analysts have rated the stock with a strong buy recommendation.
Brokers have set a 12-month consensus price objective of $8.50 for the company and are anticipating that the company will post ($0.22) EPS for the current quarter, according to Zacks. Zacks has also assigned VBI Vaccines an industry rank of 109 out of 265 based on the ratings given to its competitors.
A number of equities research analysts recently issued reports on the company. Ladenburg Thalmann assumed coverage on VBI Vaccines in a research report on Tuesday, July 26th. They issued a “buy” rating on the stock. Laidlaw assumed coverage on VBI Vaccines in a research report on Monday, October 10th. They issued a “buy” rating and a $6.00 price objective on the stock.
Shares of VBI Vaccines (NASDAQ:VBIV) traded up 0.97% on Monday, reaching $3.13. The company’s stock had a trading volume of 5,029 shares. The stock has a 50 day moving average of $3.63 and a 200-day moving average of $3.80. The firm’s market cap is $113.10 million. VBI Vaccines has a 12 month low of $3.05 and a 12 month high of $4.40.
An institutional investor recently raised its position in VBI Vaccines stock. BlackRock Fund Advisors boosted its position in shares of VBI Vaccines Inc. (NASDAQ:VBIV) by 1,701.6% during the second quarter, according to its most recent filing with the SEC. The fund owned 44,789 shares of the biopharmaceutical company’s stock after buying an additional 42,303 shares during the period. BlackRock Fund Advisors owned approximately 0.14% of VBI Vaccines worth $177,000 at the end of the most recent reporting period. 12.26% of the stock is owned by institutional investors.
VBI Vaccines Company Profile
VBI Vaccines Inc, formerly SciVac Therapeutics Inc, is a biotechnology company. The Company is engaged in developing various technologies that focus on vaccine protection. It has developed an enveloped virus like particle (eVLP) vaccine platform that allows for the design of enveloped VLP vaccines. It is involved in various projects related to human cytomegalovirus (CMV) and other antigens.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for VBI Vaccines Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VBI Vaccines Inc. and related companies with MarketBeat.com's FREE daily email newsletter.